Autopsy report · NCT05234606
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Cause of deathFunding or business
“Sponsor decision based on strategic re-alignment”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1, Phase 2
- Sponsor
- Silverback Therapeutics
- Sponsor type
- Industry
- Conditions
- Urothelial Carcinoma; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Hormone Receptor-positive/HER2-negative Breast Cancer
- Interventions
- SBT6290; SBT6290; pembrolizumab
- Participants
- 0
Trials that died the same way
- 99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
“Sponsor Decision based on strategic considerations” - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
“Strategic sponsor decision” - Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
“Strategic decision of Sponsor” - Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
“Sponsor decision due to strategic considerations” - Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
“Sponsor's strategic decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.